Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative used as an adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older. It has a longer half-life compared to other benzodiazepines.
## Primary Indications
Adjunctive treatment of seizures in Lennox-Gastaut Syndrome (LGS) in patients aged 2 years and older.
## Adult Dosing
* **Initiation:** 5 mg twice daily.
* **Titration:** May increase dose by 5 mg to 10 mg every week based on response and tolerability.
* **Usual Maintenance Dose:** 10 mg to 20 mg twice daily.
* **Maximum Dose:** 20 mg twice daily (total 40 mg/day).
## Pediatric Dosing (2 to <10 years)
* **Initiation:** 2.5 mg twice daily.
* **Titration:** May increase dose by 2.5 mg to 5 mg every week based on response and tolerability.
* **Usual Maintenance Dose:** 5 mg twice daily.
* **Maximum Dose:** 10 mg twice daily (total 20 mg/day).
## Pediatric Dosing (≥10 years)
Dosing is the same as for adults.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. Limited data suggests a reduction in dose may be necessary, though specific recommendations are not established.
* **Renal Impairment:** Use with caution. No specific dose adjustment guidelines are available.
## Contraindications
* Known hypersensitivity to clobazam or other benzodiazepines.
* Severe respiratory insufficiency.
* Severe hepatic insufficiency.
* Myasthenia gravis.
* Severe sleep apnea.
## Adverse Effects
* **Common:** Somnolence, fatigue, decreased appetite, constipation, aggression, irritability, difficulty with coordination, drooling, behavioral problems.
* **Serious:** Suicidal behavior and ideation, severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), respiratory depression, dependence and withdrawal symptoms.
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other sedatives):** Increased risk of sedation, respiratory depression, and coma.
* **CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir):** May increase clobazam concentrations.
* **CYP3A4 Inducers (e.g., carbamazepine, phenytoin, rifampin):** May decrease clobazam concentrations.
* **CNS Stimulants:** May reduce the effectiveness of stimulants.
* **Valproic Acid:** Concomitant use may increase valproic acid levels.
## Monitoring
* **Clinical Efficacy:** Monitor for seizure frequency and severity.
* **Adverse Effects:** Assess for somnolence, behavioral changes, coordination difficulties, and signs of severe skin reactions.
* **Suicidal Behavior/Ideation:** Monitor patients for the emergence or worsening of depression, unusual changes in behavior, or suicidal thoughts and behavior.
* **Dependence/Withdrawal:** Monitor for signs of tolerance and withdrawal upon discontinuation. Gradual tapering is recommended.
## Clinical Pearls
* Clobazam is typically used as an adjunctive therapy, meaning it is given in addition to other antiepileptic drugs.
* Due to its long half-life, steady-state concentrations may take several days to achieve.
* Sudden discontinuation can lead to withdrawal symptoms, including rebound seizures. Tapering of the dose is recommended upon discontinuation.
* Increased risk of serious skin reactions, particularly in patients with sulfonamide or carbamazepine hypersensitivity. Discontinue at the first sign of rash.
* The extended-release formulation may offer more consistent plasma concentrations.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant literature for complete details before making any clinical decisions. Dosing may vary based on individual patient factors and local protocols.*
